STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALLO
  4. [Form 4] Allogene Therapeutics, Inc. Insider Trading Activity

Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Allogene Therapeutics President and CEO Zachary Roberts reported equity awards rather than open-market trades. He received a grant of 476,190 stock options to buy common stock at an exercise price of $2.11 per share, expiring on July 1, 2036. Twenty-five percent of these options vest on July 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter.

Roberts was also granted 134,530 Restricted Stock Units, each representing one share of common stock. These RSUs vest in four equal annual installments over the four-year period starting July 20, 2026, subject to his continued service. The filing shows compensation-related acquisitions, with no reported stock purchases or sales in the market.

Positive

  • None.

Negative

  • None.
Insider Roberts Zachary
Role President and CEO
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 134,530 $0.00 --
Grant/Award Stock Option (Right to buy) 476,190 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 134,530 shares (Direct, null); Stock Option (Right to buy) — 476,190 shares (Direct, null)
Footnotes (1)
  1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date. 25% of the shares subject to the stock option shall vest on July 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Stock options granted 476,190 options Grant of stock options to buy common stock
Option exercise price $2.11 per share Exercise price for granted stock options
Option expiration date July 1, 2036 Expiration of stock option award
RSUs granted 134,530 RSUs Restricted Stock Units awarded to CEO
RSU vesting start July 20, 2026 First vesting date for RSU award
Initial option vesting 25% on July 1, 2027 First vesting tranche of stock options
Restricted Stock Units (RSUs) financial
"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
stock option financial
"25% of the shares subject to the stock option shall vest on July 1, 2027"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"The RSUs will vest in 4 successive equal annual installments over the four-year period"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
President and CEO financial
"Roberts Zachary, President and CEO of Allogene Therapeutics, Inc."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Roberts Zachary
(Last)(First)(Middle)
210 EAST GRAND AVE
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)07/01/2026A134,530 (1) (1)Common Stock134,530$0134,530D
Stock Option (Right to buy)$2.1107/01/2026A476,190 (2)07/01/2036Common Stock476,190$0476,190D
Explanation of Responses:
1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date.
2. 25% of the shares subject to the stock option shall vest on July 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Remarks:
/s/Earl Douglas, Attorney-in-Fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Allogene Therapeutics (ALLO) report in this Form 4 for Zachary Roberts?

The Form 4 reports that President and CEO Zachary Roberts received equity compensation awards, including stock options and Restricted Stock Units. These awards increase his potential ownership in Allogene stock over time as they vest, rather than reflecting any open-market trading activity.

How many stock options did Allogene CEO Zachary Roberts receive in this filing?

Zachary Roberts received 476,190 stock options to buy Allogene common stock at an exercise price of $2.11 per share. Twenty-five percent vest on July 1, 2027, with the remaining options vesting in 36 equal monthly installments after that initial vesting date.

What Restricted Stock Unit (RSU) award did Zachary Roberts receive from Allogene (ALLO)?

Roberts received 134,530 Restricted Stock Units, each representing one share of Allogene common stock. These RSUs vest in four equal annual installments over a four-year period starting July 20, 2026, contingent on his continued service through each applicable vesting date.

Are the transactions in Zachary Roberts’ Allogene Form 4 open-market buys or sells?

The reported transactions are not open-market buys or sells. They are compensation-related acquisitions: a grant of stock options and a grant of Restricted Stock Units. No market purchases or sales of Allogene common stock are disclosed in this Form 4 filing.

When do Zachary Roberts’ new Allogene stock options and RSUs begin vesting?

The RSUs begin vesting on July 20, 2026, in four equal annual installments. The stock options begin vesting with 25% on July 1, 2027, and the remaining option shares then vest in 36 equal monthly installments, all subject to his continued service.